...
首页> 外文期刊>Journal of the Formosan Medical Association =: Taiwan yi zhi >Treatment outcomes of locally advanced cervical cancer by histopathological types in a single institution: A propensity score matching study
【24h】

Treatment outcomes of locally advanced cervical cancer by histopathological types in a single institution: A propensity score matching study

机译:单个机构按组织病理学类型对局部晚期宫颈癌的治疗结果:倾向评分匹配研究

获取原文
           

摘要

BackgroundIn the current National Comprehensive Cancer Network (NCCN) guidelines, the standard treatment methods revealed no difference between locally advanced cervical (LAC) adenocarcinoma/adenosquamous carcinoma (AC/ASC) and LAC squamous cell carcinoma (SCC). The aim of this study was to compare the treatment outcomes of LAC AC/ASC with LAC SCC through the propensity score matching (PSM) analysis.MethodsThis retrospective study enrolled 181 LAC cancer patients who were treated with intensity modulated radiotherapy/volumetric modulated arc therapy and concurrent weekly cisplatin 30–40?mg/m2. In total, there were 151 LAC SCC patients and 30 LAC AC/ASC patients. The endpoints were overall survival (OS), disease-free survival (DFS), locoregional failure-free survival (LRFFS), and distant metastasis-free survival (DMFS). A 1:1 ratio PSM analysis was performed using the nearest neighbor method with a caliper of 0.20. Treatment outcomes were compared between 30 matched LAC SCC patients and 30 LAC AC/ASC patients.ResultsBefore a 1:1 ratio PSM, the 5-year OS, DFS, LRFFS, and DMFS in the LAC SCC group were 78.6%, 71.3%, 88.2%, and 76.2%, respectively. After a 1:1 ratio PSM, the 5-year OS, DFS, LRFFS, and DMFS in the LAC AC/ASC group were 46.0%, 43.3%, 70.0%, and 45.4%, respectively, which were all significantly inferior than the rates of 90.0%, 75.8%, 96.6%, and 78.8% in the matched LAC SCC group, respectively (p?
机译:背景技术在当前的国家综合癌症网络(NCCN)指南中,标准治疗方法显示局部晚期宫颈癌(LAC)腺癌/腺鳞癌(AC / ASC)与LAC鳞状细胞癌(SCC)之间没有区别。这项研究的目的是通过倾向评分匹配(PSM)分析来比较LAC AC / ASC和LAC SCC的治疗结果。方法这项回顾性研究招募了181名接受强度调制放疗/体积调制弧光治疗的LAC癌症患者。每周同步顺铂30–40?mg / m2。总共有151例LAC SCC患者和30例LAC AC / ASC患者。终点为总体生存期(OS),无病生存期(DFS),局部无衰竭生存期(LRFFS)和远处无转移生存期(DMFS)。使用最近邻方法(卡尺为0.20)执行1:1比例的PSM分析。比较30例匹配的LAC SCC患者和30例LAC AC / ASC患者的治疗结果。结果在1:1的PSM之前,LAC SCC组的5年OS,DFS,LRFFS和DMFS为78.6%,71.3%,分别为88.2%和76.2%。在以1:1的比率PSM后,LAC AC / ASC组的5年OS,DFS,LRFFS和DMFS分别为46.0%,43.3%,70.0%和45.4%,均显着低于匹配的LAC SCC组的肝癌发生率分别为90.0%,75.8%,96.6%和78.8%(p <0.05)。结论LAC AC / ASC的预后较LAC SCC差。为了获得更高的OS和DFS,LAC AC / ASC需要更积极地对待。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号